Roche setzt geplante Investitionen in Deutschland aus – lässt sich aber ein Türchen offen
Der Basler Medikamentenhersteller Roche ist empört über die Preisnachlässe, zu denen ihn die deutsche Regierung zwingt. Für den Fall, dass sich Berlin wieder auf die Pharmaindustrie zubewegt, signalisiert er Kompromissbereitschaft.
Swiss pharmaceutical company Roche has canceled planned investments in Germany due to government-mandated price cuts, but has left the door open for compromise. Roche's CEO, Daniel Steiners, expressed anger over the German government's policies, stating that the company has put all future investment decisions in Germany on hold.
The German law, passed in July last year, requires pharmaceutical manufacturers to provide additional discounts to help limit the high costs faced by the healthcare system. Roche is not alone in questioning the new regulations, as American pharmaceutical firms Eli Lilly and Pfizer have also planned to reduce their investments in Germany.
Roche is the largest employer in the German pharmaceutical industry, with 18,600 employees in the country, but it is also one of the largest shareholders, having invested 3.8 billion Swiss francs since 2020. Despite the controversy, Roche stated that it remains committed to investing in Germany where the regulatory conditions are reliable and the location is internationally competitive.
The company has also begun construction of a new manufacturing plant at its headquarters in Basel. However, the Swiss government's fiscal losses and the reduction in patent protection periods have prompted other major pharmaceutical companies like Novartis to redimension their German investments.
Written by urgent.news from NZZ Wirtschaft's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Investments: Government courts investors: "Germany is back" handelsblatt.com
